1. Home
  2. SXI vs CGON Comparison

SXI vs CGON Comparison

Compare SXI & CGON Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • SXI
  • CGON
  • Stock Information
  • Founded
  • SXI 1955
  • CGON 2010
  • Country
  • SXI United States
  • CGON United States
  • Employees
  • SXI N/A
  • CGON N/A
  • Industry
  • SXI Industrial Machinery/Components
  • CGON
  • Sector
  • SXI Industrials
  • CGON
  • Exchange
  • SXI Nasdaq
  • CGON NYSE
  • Market Cap
  • SXI 2.3B
  • CGON 2.0B
  • IPO Year
  • SXI N/A
  • CGON 2024
  • Fundamental
  • Price
  • SXI $166.30
  • CGON $26.10
  • Analyst Decision
  • SXI Strong Buy
  • CGON Strong Buy
  • Analyst Count
  • SXI 3
  • CGON 11
  • Target Price
  • SXI $223.33
  • CGON $63.30
  • AVG Volume (30 Days)
  • SXI 119.5K
  • CGON 942.7K
  • Earning Date
  • SXI 07-31-2025
  • CGON 08-07-2025
  • Dividend Yield
  • SXI 0.78%
  • CGON N/A
  • EPS Growth
  • SXI N/A
  • CGON N/A
  • EPS
  • SXI 5.04
  • CGON N/A
  • Revenue
  • SXI $748,252,000.00
  • CGON $662,000.00
  • Revenue This Year
  • SXI $9.67
  • CGON N/A
  • Revenue Next Year
  • SXI $12.91
  • CGON $21,843.29
  • P/E Ratio
  • SXI $32.32
  • CGON N/A
  • Revenue Growth
  • SXI 2.67
  • CGON 224.51
  • 52 Week Low
  • SXI $128.85
  • CGON $14.80
  • 52 Week High
  • SXI $212.66
  • CGON $40.47
  • Technical
  • Relative Strength Index (RSI)
  • SXI 60.11
  • CGON 48.77
  • Support Level
  • SXI $154.57
  • CGON $24.50
  • Resistance Level
  • SXI $158.49
  • CGON $27.09
  • Average True Range (ATR)
  • SXI 4.03
  • CGON 1.44
  • MACD
  • SXI 0.10
  • CGON -0.08
  • Stochastic Oscillator
  • SXI 78.78
  • CGON 35.56

About SXI Standex International Corporation

Standex International Corp is an industrial manufacturer of different products and services used in commercial and industrial markets. It has five reportable segments; Electronics; Engraving; Scientific; Engineering Technologies and Specialty Solutions. The maximum revenue is generated from its Electronics segment which is a component and value-added services provider of both sensing and switching technologies as well as magnetic power conversion components and assemblies, like custom wound transformers and inductors, current sense technology, value-added assemblies, and mechanical packaging among others. Geographically, it derives key revenue from the United States and the rest from Asia Pacific, Europe, Middle East and South Africa (EMEA), and other regions.

About CGON CG ONCOLOGY INC

CG Oncology Inc is a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients afflicted with bladder cancer. The company's lead candidate, cretostimogene grenadenorepvec, is a targeted oncolytic intravesically delivered immunotherapy agent that is in two phase three trials (one high-risk BCG unresponsive NMIBC trial and one intermediate-risk NMIBC trial) and a phase two clinical study with a checkpoint inhibitor for high-risk BCG unresponsive NMIBC disease.

Share on Social Networks: